Origin recognition complex subunit 1 functions as an oncogenic driver and therapeutic target in cancer.

Yixuan Ding, Shiwei Cai, Jinzhou Cai, Zhanpeng Wang, Zigui Zhu

Abstract readReview

In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yixuan DingDepartment of Intensive Care, The Nanhua Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Shiwei CaiDepartment of Thoracic Cardiovascular Surgery, Hengyang Medical School, The First Affiliated Hospital of University of South China, University of South China, Hengyang, Hunan, China.

Jinzhou CaiDepartment of Cardiovascular Surgery, Second Xiangya Hospital, Central South University, Changsha, China.

Zhanpeng WangDepartment of Thoracic Cardiovascular Surgery, Hengyang Medical School, The First Affiliated Hospital of University of South China, University of South China, Hengyang, Hunan, China.

Zigui ZhuDepartment of Intensive Care, The Nanhua Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China. 752569522@qq.com.

Funding

the Research project of Health Commission of Hunan Province 202217014684

6 · The paper itself

Abstract

ORC1 is a core protein governing DNA replication initiation and cell cycle regulation, exhibiting significant overexpression in multiple malignancies where it correlates with advanced disease stage and poor prognosis. It drives tumor progression through diverse mechanisms including activation of ERK/JNK and Wnt signaling pathways, inhibition of ferroptosis via SLC7A11, and promotion of epithelial-mesenchymal transition. Its expression is regulated through multiple layers including m6A modification by IGF2BP1, the XIST/miR-140-5p axis, transcription factors like ETV4, and epigenetic regulators including EZH2. ORC1 represents a promising therapeutic target, as its inhibition induces replication stress, cell cycle arrest, and enhances sensitivity to existing chemotherapeutic agents. Future research should focus on developing specific ORC1 inhibitors and exploring their synergistic potential with immunotherapy and targeted therapies.

Indexed as

Cancer biomarkerCell cycle regulationDNA replication initiationEpigenetic regulationERK/JNK signaling pathwayORC1Targeted therapy

Identifiers

PMID41379386

DOI10.1007/s12672-025-04257-6

PMCPMC12804511

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.